EPS for Aptose Biosciences Inc. (APTO) Expected At $-0.13

March 14, 2018 - By Marie Mckinney

 EPS for Aptose Biosciences Inc. (APTO) Expected At $ 0.13

Analysts expect Aptose Biosciences Inc. (NASDAQ:APTO) to report $-0.13 EPS on March, 27 after the close.They anticipate $0.06 EPS change or 31.58 % from last quarter’s $-0.19 EPS. After having $-0.11 EPS previously, Aptose Biosciences Inc.’s analysts see 18.18 % EPS growth. The stock increased 3.88% or $0.14 during the last trading session, reaching $3.75. About 612,960 shares traded or 7.04% up from the average. Aptose Biosciences Inc. (NASDAQ:APTO) has declined 60.81% since March 14, 2017 and is downtrending. It has underperformed by 77.51% the S&P500.

Aptose Biosciences Inc. (NASDAQ:APTO) Ratings Coverage

Among 5 analysts covering Aptose Biosciences (NASDAQ:APTO), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Aptose Biosciences had 15 analyst reports since August 7, 2015 according to SRatingsIntel. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) has “Neutral” rating given on Friday, November 20 by Roth Capital. The firm has “Buy” rating given on Monday, June 13 by Roth Capital. RBC Capital Markets maintained Aptose Biosciences Inc. (NASDAQ:APTO) on Wednesday, November 11 with “Outperform” rating. The stock has “Outperform” rating by RBC Capital Markets on Wednesday, November 16. The rating was initiated by H.C. Wainwright on Thursday, June 8 with “Hold”. The stock of Aptose Biosciences Inc. (NASDAQ:APTO) has “Buy” rating given on Thursday, September 7 by H.C. Wainwright. The rating was maintained by H.C. Wainwright with “Hold” on Wednesday, August 9. TH Capital downgraded it to “Neutral” rating and $4 target in Friday, November 20 report. The rating was maintained by H.C. Wainwright on Monday, October 30 with “Buy”. The firm earned “Buy” rating on Wednesday, December 13 by H.C. Wainwright.

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company has market cap of $99.63 million. The Company’s lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. It currently has negative earnings. The firm has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.

Another recent and important Aptose Biosciences Inc. (NASDAQ:APTO) news was published by Globenewswire.com which published an article titled: “Aptose Biosciences Announces Exclusive License Agreement for Dual BET/Kinase …” on March 07, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.